Talk:Dacomitinib
Appearance
This is the talk page for discussing improvements to the Dacomitinib article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||||||||||
|
Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Dacomitinib.
|
Improved PFS in NSCLC - ASCO 2017
[edit]Could mention Dacomitinib Sets PFS Record in Phase III NSCLC Trial. 2017 : "...Dacomitinib treatment extended median progression-free survival by 5.5 months versus gefitinib -- to 14.7 months -..." & toxicity issues - Rod57 (talk) 10:05, 9 June 2017 (UTC)
Clarify inhibitory effect on normal and various mutated forms of EGFR
[edit]The trials seem to be on patients with mutated EGFR but does it also inhibit normal EGFR ? - Rod57 (talk) 10:17, 9 June 2017 (UTC)